371 related articles for article (PubMed ID: 28823521)
21. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
[TBL] [Abstract][Full Text] [Related]
22. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
23. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
[TBL] [Abstract][Full Text] [Related]
25. The IL-2 cytokine family in cancer immunotherapy.
Sim GC; Radvanyi L
Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
27. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
28. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer.
Kurz E; Hirsch CA; Dalton T; Shadaloey SA; Khodadadi-Jamayran A; Miller G; Pareek S; Rajaei H; Mohindroo C; Baydogan S; Ngo-Huang A; Parker N; Katz MHG; Petzel M; Vucic E; McAllister F; Schadler K; Winograd R; Bar-Sagi D
Cancer Cell; 2022 Jul; 40(7):720-737.e5. PubMed ID: 35660135
[TBL] [Abstract][Full Text] [Related]
29. Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma.
Hira SK; Mondal I; Manna PP
Cytotherapy; 2015 May; 17(5):647-64. PubMed ID: 25769790
[TBL] [Abstract][Full Text] [Related]
30. Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials.
Törnroos H; Hägerstrand H; Lindqvist C
Anticancer Res; 2019 Jan; 39(1):107-112. PubMed ID: 30591446
[TBL] [Abstract][Full Text] [Related]
31. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
32. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2.
Seidel MG; Freissmuth M; Pehamberger H; Micksche M
Naunyn Schmiedebergs Arch Pharmacol; 1998 Sep; 358(3):382-9. PubMed ID: 9774227
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic applications of IL-15.
Croce M; Orengo AM; Azzarone B; Ferrini S
Immunotherapy; 2012 Sep; 4(9):957-69. PubMed ID: 23046239
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
35. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber HP; Sapra P; Loganzo F; May C
Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
[TBL] [Abstract][Full Text] [Related]
36. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
37. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
[TBL] [Abstract][Full Text] [Related]
38. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.
Guo Y; Luan L; Patil NK; Sherwood ER
Cytokine Growth Factor Rev; 2017 Dec; 38():10-21. PubMed ID: 28888485
[TBL] [Abstract][Full Text] [Related]
39. IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity.
Hansen ML; Woetmann A; Krejsgaard T; Kopp KL; Søkilde R; Litman T; Straten PT; Geisler C; Wasik MA; Odum N; Eriksen KW
Mol Immunol; 2011 Sep; 48(15-16):2087-93. PubMed ID: 21813181
[TBL] [Abstract][Full Text] [Related]
40. Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?
Mastroianni CM; d'Ettorre G; Forcina G; Vullo V
Trends Immunol; 2004 Mar; 25(3):121-5. PubMed ID: 15036038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
